PTC Therapeutics(PTCT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [4][15] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [5] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [18] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [4][10] - DMD franchise revenue for Q4 2025 was $66 million, with Translarna and Emflaza contributing $39 million and $27 million, respectively [15] - Evrysdi royalty revenue for full-year 2025 was $244 million [15] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide by the end of 2025 [11] - The U.S. accounted for the majority of Sephience revenue, with $81 million generated in Q4 2025 [10] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, including Japan and Brazil [7][13] Company Strategy and Development Direction - The main focus for 2026 is to continue the strong momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and expansion into additional geographies [6][7] - The company plans to advance several programs from its innovative R&D platforms, including RNA splicing and ferroptosis inflammation [9] - The company aims to reach cash flow break-even in 2026, a significant milestone [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Sephience's potential, citing a multi-billion dollar global revenue opportunity due to its differentiated profile and large unmet need [7] - The management highlighted the importance of social media in raising awareness and driving patient engagement for Sephience [29] - The company anticipates continued strong performance from its mature products despite headwinds in the DMD franchise [14] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025 [16] - The FDA has requested an additional study for vatiquinone, which the company plans to pursue [34][36] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance for 2026 is $700 million-$800 million, with the majority expected from Sephience, and adjustments may be made as visibility improves [20][21] Question: How are lost to follow-up patients becoming aware of Sephience? - Social media has played a significant role in raising awareness among patients who were previously lost to follow-up, leading to increased engagement with healthcare providers [29] Question: Can you provide details on the additional study requested by the FDA for vatiquinone? - The FDA suggested an open-label or single-arm study with a natural history comparator group, and the company plans to meet with the FDA to finalize the protocol [36][39] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with most dropouts being patient decisions rather than clinical reasons [44] Question: How is the pricing and reimbursement process for Sephience in Germany? - The company has submitted its HTA dossier and is in discussions for pricing and reimbursement, expecting to maintain a high list price based on strong clinical data [51]